Collectively, these findings identify CALD1 as a novel regulator of VIC phenotypic plasticity and osteogenic transition during CAVD progression, providing mechanistic insight and a target for potential AS therapy. The gene discussed is CALD1; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.